Multicenter Randomized Trial of Non-inferiority Between Glyburide and Insulin for the Treatment of Gestational Diabetes (INDAO)
This clinical trial aims to test whether glibenclamide is non-inferior to insulin for the treatment of gestational diabetes.
|Study Design:||Allocation: Randomized
Endpoint Classification: Bio-equivalence Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Multicenter Randomized Trial of Non-inferiority Between Glyburide and Insulin for the Treatment of Gestational Diabetes|
- Composite criterion of neonatal complications associated with gestational diabetes: macrosomia or birth weight ≥ 90th percentile for gestational age, neonatal hypoglycemia and neonatal hyperbilirubinemia [ Time Frame: At birth until neonatal discharge from maternity ] [ Designated as safety issue: No ]
- Rates of caesarean section, preterm delivery rate, neonatal mortality rate, number of neonatal and maternal trauma related to delivery, number of respiratory distress, number of prenatal visits, number of days of hospitalization [ Time Frame: during pregnancy until maternal discharge from maternity ] [ Designated as safety issue: No ]Maternal glycemic control, rates of caesarean section, preterm delivery rate, neonatal mortality rate, number of neonatal and maternal trauma related to delivery, number of respiratory distress, number of prenatal visits, number of days of hospitalization and maternal satisfaction
|Study Start Date:||January 2012|
|Estimated Study Completion Date:||November 2015|
|Estimated Primary Completion Date:||June 2015 (Final data collection date for primary outcome measure)|
Active Comparator: Insulin
standard protocol of insulin treatment for gestational diabetes
initial dose 2.5 mg per day increased if necessary until 10mg twice a day if glycemia is not controlled
In patients with gestational diabetes, a therapeutic treatment with a diet, a blood glucose monitoring and, if necessary, treatment with insulin is associated with reduced neonatal complications. Although the effectiveness of insulin is proven, this therapy has many drawbacks, especially in terms of implementation and monitoring by women. An alternative is the use of oral antidiabetic agents like glibenclamide.
Assumption: Glibenclamide is non-inferior to insulin for the treatment of gestational diabetes.
Main objective: To test the oral Glibenclamide is non-inferior to subcutaneous insulin for the occurrence of perinatal complications in the management of pregnant women developing gestational diabetes and requiring treatment other than dietary.
Secondary Objective: To test the noninferiority of two treatments on maternal glycemic control and maternal complications.
Sample size: With a 80% power and a significance level of 5%, 450 subjects per group are required to show that treatment with glibenclamide is not considered inferior to treatment with insulin if the frequency of outcome composite does not exceed 25% with glibenclamide, whereas it was 18% with insulin (calculated with a non-inferiority margin of 7% and considering that 20% of patients treated with glyburide and Insulin for change half of the patients accept randomization).
Progress of the study: Inclusion of women between 24 and 34 weeks. Randomization between Insulin and Glibenclamide after failure of 10 days of dietary treatment well done. Failure defined by at least 2 abnormal values of glycemia: fasting glucose ≥ 0.95 g / l and/or a postprandial 2h ≥ 1.20 g / l.
Women will receive either insulin according to the usual protocol or Glibenclamide at an initial dose of 2.5 mg / once daily in the morning before breakfast. So long as the glycemic targets will not be reached doses are gradually increased stepwise every 4 days until day 21 (20mg/j) . Patients who have not reached the glycemic targets at this highest dose will have a change in treatment for insulin at day 21. Routine monitoring of pregnant women with gestational diabetes, up to a week after delivery Number of clinical sites: 15 Perspective: Use of Glibenclamide as a first line treatment of gestational diabetes requiring drug treatment.
|Contact: Marie-Victoire Senat, PhD||+33 1 45 21 77 firstname.lastname@example.org|
|Contact: Jean Bouyer, PhD||+33 1 45 21 20 email@example.com|
|Paris, France, 94270|
|Contact: Laurence BUSSIERES +33144841779 ext 1779 firstname.lastname@example.org|
|Contact: Shoreh AZIMI +33144841779 ext 1779 email@example.com|
|Principal Investigator: Marie-Victoire SENAT|
|Principal Investigator:||Marie-Victoire SENAT, PhD||AP-HP|